Advertisement
News
Advertisement

Biogen Q1 numbers up on strength of MS drug sales

Thu, 04/21/2011 - 5:35am
Mass High Tech: The Journal of New England Technology

Biogen Idec Inc. (Nasdaq: BIIB) said first-quarter revenue was up 9 percent over the same period a year earlier, driven by the performance of its two blockbuster multiple sclerosis infusion treatments.

The Weston-based biotechnology company reported that revenue was $1.2 billion, with a profit of $294 million, up 35 percent from the first quarter of 2010. The gains were driven by the MS treatments Tysabri, which increased 15 percent to $251 million, and Avonex, which increased 8 percent to $642 million. Quarterly revenue for Rituxan was flat year-over-year, at $256 million.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading